Nocardia pseudobrasiliensis Co-infection in SARS-CoV-2 Patients

During the SARS-CoV-2 pandemic, few cases of Nocar­dia spp. co-infection have been reported during or after a COVID-19 infection. Nocardia spp. are gram-positive aerobic actinomycetes that stain partially acid-fast, can infect immunocompromised patients, and may cause dis­seminated disease. We repor...

Descripción completa

Detalles Bibliográficos
Autores principales: Stamos, Daniel Beau, Barajas-Ochoa, Aldo, Raybould, Jillian E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2023
Materias:
Synopsis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045714/
https://www.ncbi.nlm.nih.gov/pubmed/36958028
http://dx.doi.org/10.3201/eid2904.221439
Descripción
Sumario:During the SARS-CoV-2 pandemic, few cases of Nocar­dia spp. co-infection have been reported during or after a COVID-19 infection. Nocardia spp. are gram-positive aerobic actinomycetes that stain partially acid-fast, can infect immunocompromised patients, and may cause dis­seminated disease. We report the case of a 52-year-old immunocompromised man who had Nocardia pseudobrasiliensis pneumonia develop after a SARS-CoV-2 in­fection. We also summarize the literature for no­cardiosis and SARS-CoV-2 co-infections. Nocardia spp. infection should remain a part of the differential diagnosis for pneumonia in immunocompromised hosts, regardless of other co-infections. Sulfonamide/carbapenem combina­tions are used as empiric therapy for nocardiosis; species identification and susceptibility testing are required to se­lect the optimal treatment for each patient.

Ejemplares similares